S. Frye

发表

The human genome and drug discovery after a decade. Roads (still) not taken

Gary D Bader, T. Willson, Ruth Isserlin, 2011, 1102.0448.

Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era.

S. Frye, 1999, Chemistry & biology.

Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors.

S. Frye, F. Liu, C. Arrowsmith, 2013, Journal of medicinal chemistry.

Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen™-Based Assay for Antagonists of Methyl-Lysine Binding Proteins

Tim J. Wigle, S. Frye, W. Janzen, 2010, Journal of biomolecular screening.

Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

S. Frye, B. Hendriks, P. Harari, 2015, Molecular Cancer Therapeutics.

Tackling reproducibility in academic preclinical drug discovery

Michelle R. Arkin, Marcie A. Glicksman, P. Jeffrey Conn, 2015, Nature Reviews Drug Discovery.

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Bin Wang, Jing Liu, Yi Zhang, 2011, Cancer cell.

US academic drug discovery

Stephen Frye, Teresa P. Edwards, S. Frye, 2011, Nature Reviews Drug Discovery.

The art of the chemical probe.

Stephen V Frye, S. Frye, 2010, Nature chemical biology.

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.

P. A. Harris, L. Kuyper, S. Frye, 2001, Journal of medicinal chemistry.

Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.

S. Frye, Frances M. Potjewyd, C. Foley, 2019, ACS chemical biology.

Writing and Rewriting the Epigenetic Code of Cancer Cells: From Engineered Proteins to Small Molecules

S. Frye, P. Blancafort, Jian Jin, 2013, Molecular Pharmacology.

Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.

Xi-Ping Huang, B. Roth, S. Frye, 2013, Journal of medicinal chemistry.

A cellular chemical probe targeting the chromodomains of Polycomb Repressive Complex 1

Nancy Cheng, Su Qin, Bradley M Dickson, 2015, Nature chemical biology.

Canonical PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing

S. Frye, Ramesh Yelagandula, Jingkui Wang, 2019, Nature Communications.

Discovery of a chemical probe for the L3MBTL3 methyl-lysine reader domain

A. Emili, J. Greenblatt, Xi-Ping Huang, 2012, Nature chemical biology.

Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.

S. Frye, L. Kelly, C. Pepe-Ranney, 2015, Chemistry & biology.

Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.

S. Frye, R. Mook, M. Moss, 1995, Biochemistry.

Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism.

J. D. Stuart, S. Frye, P. Kuzmič, 1996 .

Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism.

J. D. Stuart, S. Frye, P. Kuzmič, 1996, Biochemistry.

MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.

M. Gilbert, Wei Zhang, S. Frye, 2020, Neuro-oncology advances.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, A. Tan, 2013, The Journal of clinical investigation.

A High-Throughput Screening-Compatible Strategy for the Identification of Inositol Pyrophosphate Kinase Inhibitors

S. Frye, K. Pearce, Huanchen Wang, 2016, PloS one.

Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors

S. Frye, M. Machius, M. Miley, 2017, ChemMedChem.

Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia

S. Frye, H. Earp, A. Hill, 2015, Oncotarget.

UNC1062, a new and potent Mer inhibitor.

S. Frye, W. Janzen, H. Earp, 2013, European journal of medicinal chemistry.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

S. Frye, W. Janzen, M. Machius, 2013, Journal of medicinal chemistry.

THERE ARE NO CONFLICTS OF INTEREST TO DISCLOSE

S. Frye, S. Pattenden, M. Onaitis, 2015 .

Tumor Endothelial Cells with Distinct Patterns of TGFβ-Driven Endothelial-to-Mesenchymal Transition.

S. Frye, S. Pattenden, M. Onaitis, 2015, Cancer research.

TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma

S. Frye, Yuewei Zhang, Xiaodong Wang, 2019, Cancer Immunology Research.

AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery

T. Willson, S. K. R. Guduru, S. Frye, 2022, Alzheimer's & dementia.

Discovery and Characterization of Peptide Inhibitors for CIB1.

S. Frye, K. Pearce, L. Parise, 2020, ACS chemical biology.

MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members

S. Frye, H. Earp, Xiaodong Wang, 2018, Clinical Cancer Research.

Too many roads not taken

Gary D Bader, T. Willson, Ruth Isserlin, 2011, Nature.

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models

Kristen M. Jacobsen, S. Frye, J. Tyner, 2016, Clinical Cancer Research.

A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.

Peter A. DiMaggio, Tim J. Wigle, B. Garcia, 2011, Nature chemical biology.

Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase.

S. Frye, D. Hermann, H. N. Bramson, 1998, Pharmaceutical biotechnology.

The MERTK / FLT 3 inhibitor MRX-2843 overcomes resistance-conferring FLT 3 mutations in acute myeloid leukemia

S. Frye, C. Jordan, Catherine C. Smith, 2018 .

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

S. Frye, H. Earp, C. Jordan, 2016, JCI insight.

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

S. Frye, T. Owonikoko, S. Ramalingam, 2022, The Journal of clinical investigation.

High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility

S. Frye, W. Janzen, J. Simon, 2016, Proceedings of the National Academy of Sciences.

CHEMICAL GENETIC AND EPIGENETICS: Chemical probes for methyl lysine reader domains

S. Frye, L. James, 2016 .

Small-Molecule Modulation of Methyl-Lysine-Mediated Interactions

S. Frye, L. James, 2015 .

TNFα converting enzyme

M. Lambert, S. Frye, M. Vitek, 1999 .

Retraction of "The L3MBTL3 Methyl-Lysine Reader Domain Functions As a Dimer".

S. Frye, S. Pattenden, Brandi M Baughman, 2017, ACS chemical biology.

Discovery of Hit Compounds for Methyl-lysine Reader Proteins from a Target Class DNA-Encoded Library.

S. Frye, K. Pearce, M. Vedadi, 2022, SLAS discovery : advancing life sciences R & D.

MerTK as a therapeutic target in glioblastoma

C. Miller, M. Gilbert, S. Frye, 2018, Neuro-oncology.

Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.

S. Frye, C. Arrowsmith, M. Vedadi, 2011, Journal of medicinal chemistry.

Erratum: A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells (Nature Chemical Biology (2011) 7 (401-404))

Peter A. DiMaggio, Tim J. Wigle, B. Garcia, 2011 .

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.

Kristen M. Jacobsen, S. Frye, H. Earp, 2018, JCI insight.

Targeting Chromatin Readers

S. Frye, L. James, 2013, Clinical pharmacology and therapeutics.

Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.

S. Frye, W. Janzen, C. Arrowsmith, 2013, Journal of medicinal chemistry.

An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.

K. Hahn, Xi-Ping Huang, B. Roth, 2013, ACS chemical biology.

The discovery of potent cRaf1 kinase inhibitors.

P. A. Harris, S. Frye, K. Lackey, 2000, Bioorganic & medicinal chemistry letters.

Aymmetric synthesis of (R) - and (S)-citramalate in high enantiomeric purity

S. Frye, E. Eliel, 1985 .

Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.

M. K. James, S. Frye, D. Hermann, 1997, The Journal of pharmacology and experimental therapeutics.

Chelates as intermediates in nucleophilic additions to alkoxy ketones according to Cram's rule (cyclic model)

S. Frye, E. Eliel, Xiangning Chen, 1992 .

Are chelates truly intermediates in cram's chelate rule?

S. Frye, E. Eliel, Xiangning Chen, 1990 .

A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity.

S. Frye, R. Hunter, R. Crosby, 2001, Anti-cancer drug design.

6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.

J. A. Ray, S. Frye, R. Mook, 1994, Journal of medicinal chemistry.

Rapid-injection nuclear magnetic resonance investigation of the reactivity of .alpha.- and .beta.-alkoxy ketones with dimethylmagnesium: kinetic evidence for chelation

S. Frye, E. Eliel, R. Cloux, 1987 .

Asymmetric synthesis and Cram’s (chelate) rule

S. Frye, E. Eliel, Xiangning Chen, 1991 .

Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.

S. Frye, D. Drewry, Yuewei Zhang, 2018, Journal of medicinal chemistry.

Chiral 1,3‐Oxathiane from (+)‐Pulegone: Hexahydro‐4,4,7‐trimethyl‐4H‐1,3‐benzoxathiin

S. Frye, E. Eliel, J. Lynch, 2003 .

Chelates as Intermediates in Nucleophilic Additions to Alkoxy Ketones According to Cram′s Rule (Cyclic Model).

S. Frye, E. Eliel, Xiangning Chen, 1992 .

Are Chelates Truly Intermediates in Cram′s Chelate Rule?

S. Frye, E. Eliel, Xiangning Chen, 1990 .

The promise and peril of chemical probes.

John P. Overington, Jian Jin, Matthieu Schapira, 2015, Nature chemical biology.

Synthesis of 2-Aminobenzophenones via Rapid Halogen-Lithium Exchange in the Presence of a 2-Amino-N-methoxy-N-methylbenzamide.

S. Frye, M. Johnson, N. L. Valvano, 1991 .

Erratum: The promise and peril of chemical probes (Nature Chemical Biology (2015) 11 (536-541))

John P. Overington, Jayme L. Dahlin, Christopher M. Austin, 2015 .

6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase.

S. Frye, R. Mook, P. Maloney, 1993, Journal of medicinal chemistry.

6-azacholesten-3-ones substituees

S. Frye, C. Haffner, 1996 .

6-Azasteroids: Potent Dual Inhibitors of Human Type 1 and 2 Steroid 5. alpha.-Reductase.

M. K. James, S. Frye, T. Tippin, 1994 .

Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor.

S. Frye, 2006, Current topics in medicinal chemistry.

MS0621, a novel small-molecule modulator of Ewing sarcoma chromatin accessibility, interacts with an RNA-associated macromolecular complex and influences RNA splicing

Kyle V. Butler, S. Frye, Y. Xiong, 2023, Frontiers in Oncology.

Donated chemical probes for open science

Anton Simeonov, Steve Hitchcock, Stefan Laufer, 2018, eLife.

Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7.

S. Frye, T. Kenakin, G. Wang, 2019, Cell chemical biology.

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

Jian Jin, Charles M. Perou, Katherine A. Hoadley, 2012, Cell.

Discovery of selective activators of PRC2 mutant EED-I363M

S. Frye, C. Arrowsmith, M. Vedadi, 2019, Scientific Reports.

Experiences in Academic and Industry Partnerships – Forging a Path to Translational Drug Discovery

Vadim J. Gurvich, N. Carragher, S. Frye, 2021 .

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.

B. Garcia, D. Zheng, S. Frye, 2014, Blood.

Structural basis of paralog-specific KDM2A/B nucleosome recognition

S. Frye, Emily M. Wilkerson, D. Goldfarb, 2023, Nature Chemical Biology.

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

S. Frye, J. Tyner, H. Earp, 2021, Cancers.

Drug Discovery Toward Antagonists of Methyl-Lysine Binding Proteins

S. Frye, Cen Gao, L. Ingerman, 2011, Current chemical genomics.

Targeting Methyl Lysine

S. Frye, T. Heightman, Jian Jin, 2010 .

Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8

Kyle V. Butler, S. Frye, W. Janzen, 2014, Journal of medicinal chemistry.

Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.

Anton Simeonov, Feng Liu, Ajit Jadhav, 2010, Journal of medicinal chemistry.

Accessing protein methyltransferase and demethylase enzymology using microfluidic capillary electrophoresis.

S. Frye, W. Janzen, Jian Jin, 2010, Chemistry & biology.

Epigenetics: tools and technologies.

S. Frye, W. Janzen, Jian Jin, 2010, Drug discovery today. Technologies.

Epigenetics: Tools and Technologies.

S. Frye, W. Janzen, Jian Jin, 2010, Drug discovery today. Technologies.

Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.

Anton Simeonov, Feng Liu, Ajit Jadhav, 2009, Journal of medicinal chemistry.

Abstract 240: MERTK inhibition induces an anti-leukemia dendritic cell - T cell axis while TYRO3 inhibition protects through a separate mechanism

S. Frye, Xiaodong Wang, H. Earp, 2022, Cancer Research.

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

D. Newton, S. Frye, W. Janzen, 2014, Journal of medicinal chemistry.

Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma

S. Frye, Carolina P. Lin, H. Earp, 2019, Proceedings of the National Academy of Sciences.

Discovery and Characterization of Peptide Inhibitors for Calcium and Integrin Binding Protein 1

S. Frye, K. Pearce, L. Parise, 2020 .

A General TR-FRET Assay Platform for High-Throughput Screening and Characterizing Inhibitors of Methyl-Lysine Reader Proteins

S. Frye, K. Pearce, L. James, 2019, SLAS discovery : advancing life sciences R & D.

Drug discovery in academic institutions.

S. Frye, 2013, Hematology. American Society of Hematology. Education Program.

Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency

S. Frye, D. Dittmer, B. Damania, 2018, PLoS pathogens.

AMP Is an Adenosine A1 Receptor Agonist*

Jian Jin, William P. Janzen, Mark J. Zylka, 2012, The Journal of Biological Chemistry.

Mer Receptor Tyrosine Kinase

S. Frye, Xiaodong Wang, 2014 .

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer

Michael J. Emanuele, Laura E. Herring, S. Frye, 2019, Science Signaling.

Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine.

S. Frye, C. Foley, L. James, 2021, Current opinion in chemical biology.

Design, synthesis, and protein methyltransferase activity of a unique set of constrained amine containing compounds.

S. Frye, Liping Peng, L. James, 2016, Bioorganic & medicinal chemistry letters.

The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.

S. Frye, W. Janzen, C. Arrowsmith, 2013, MedChemComm.

Peptide Technologies in the Development of Chemical Tools for Chromatin‐Associated Machinery

S. Frye, Kelsey N. Lamb, L. James, 2017 .

The L3MBTL3 Methyl-Lysine Reader Domain Functions As a Dimer.

S. Frye, S. Pattenden, Brandi M Baughman, 2016, ACS chemical biology.

Biophysical probes reveal a "compromise" nature of the methyl-lysine binding pocket in L3MBTL1.

Cen Gao, Dmitri Kireev, Stephen Frye, 2011, Journal of the American Chemical Society.

Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

S. Frye, S. Eckhardt, J. Tentler, 2018, Molecular Cancer Therapeutics.

UNC5293, a potent, orally available and highly MERTK-selective inhibitor.

S. Frye, Xiaodong Wang, H. Earp, 2021, European journal of medicinal chemistry.

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme

S. Frye, M. Varella‐Garcia, J. Kowalski, 2016, PloS one.

Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.

S. Frye, W. Janzen, M. Machius, 2013, Journal of medicinal chemistry.

Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.

S. Frye, W. Janzen, M. Machius, 2012, ACS medicinal chemistry letters.

Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Amy Lynnette Van Deusen, S. Frye, W. Janzen, 2012 .

Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology

T. Willson, S. Frye, Jessica E. Young, 2022, Alzheimer's & dementia.

Development of [18F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease.

David M. Shackleford, S. Frye, J. Baell, 2021, European journal of medicinal chemistry.

AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery

T. Willson, S. Frye, Jessica E. Young, 2021, bioRxiv.

MerTK activity is not necessary for the proliferation of glioblastoma stem cells.

S. Frye, J. Baell, A. Recasens, 2021, Biochemical pharmacology.

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents

S. Frye, P. Harari, K. Davies, 2018, Molecular Cancer Therapeutics.

Discovery of β-Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy

Maria F. Sassano, V. Setola, Xi-Ping Huang, 2011, Proceedings of the National Academy of Sciences.

Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia

James S. Duncan, S. Frye, R. Christopherson, 2013, PloS one.

Target class drug discovery.

S. Frye, L. James, Kimberly D. Barnash, 2017, Nature chemical biology.

Orally active adenosine A(1) receptor agonists with antinociceptive effects in mice.

Joseph E. Rittiner, V. Setola, S. Frye, 2012, Journal of medicinal chemistry.

Reprogramming CBX8-PRC1 function with a positive allosteric modulator

S. Frye, H. Lenz, G. Wang, 2021, bioRxiv.

The Lipid Kinase PIP5K1C Regulates Pain Signaling and Sensitization

S. Frye, W. Janzen, M. Zylka, 2014, Neuron.

Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.

Maria F. Sassano, V. Setola, M. F. Sassano, 2012, Journal of medicinal chemistry.

Discovery of an H3K36me3-Derived Peptidomimetic Ligand with Enhanced Affinity for Plant Homeodomain Finger Protein 1 (PHF1).

S. Frye, T. Kutateladze, L. James, 2021, Journal of medicinal chemistry.

Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.

S. Frye, K. Pearce, Huanchen Wang, 2019, Journal of medicinal chemistry.

The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells

Rochelle L. Tiedemann, S. Frye, B. Strahl, 2020, Epigenetics & chromatin.

Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1.

Yunxiang Mu, Bradley M Dickson, Brian D Strahl, 2015, ACS chemical biology.

Design and Construction of a Focused DNA-Encoded Library for Multivalent Chromatin Reader Proteins

S. Hammond, S. Frye, K. Pearce, 2020, Molecules.

Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors.

B G Benson, A M Hassell, P. A. Harris, 2001, Science.

Discovery of Potent Peptidomimetic Antagonists for Heterochromatin Protein 1 Family Proteins

S. Frye, K. Pearce, Kelsey N. Lamb, 2021, ACS omega.

Discovery of Potent Peptidomimetic Antagonists for Heterochromatin Protein 1 Family Proteins

S. Frye, K. Pearce, Kelsey N. Lamb, 2021, ACS Omega.

Data-driven construction of anti-tumor agents with controlled polypharmacology.

Laura E. Herring, S. Frye, M. Miley, 2019, Journal of the American Chemical Society.

Chromodomain Ligand Optimization via Target-Class Directed Combinatorial Repurposing.

S. Frye, D. Kireev, Kelsey N. Lamb, 2016, ACS chemical biology.

Canonical PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing

S. Frye, Ramesh Yelagandula, Jingkui Wang, 2019, Nature Communications.

Target 2035 – update on the quest for a probe for every protein

G. A. Bezerra, T. Willson, G. Superti-Furga, 2021, RSC medicinal chemistry.

Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment

S. Frye, H. Earp, Xiaodong Wang, 2023, Frontiers in Immunology.

Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.

S. Frye, C. Arrowsmith, M. Vedadi, 2017, ACS combinatorial science.

Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia

S. Frye, H. Earp, A. Hill, 2016 .

Abstract 1736: A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition

S. Frye, T. P. Newton, H. Earp, 2014 .

Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1.

Alexander T. Adams, S. Knapp, S. Frye, 2018, Biochemistry.

The small‐molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis

S. Frye, X. Wang, H. Earp, 2018, Journal of thrombosis and haemostasis : JTH.

UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo

S. Frye, W. Janzen, H. Earp, 2013, Molecular Cancer Therapeutics.

SETDB1 Triple Tudor Domain Ligand, (R,R)-59, Promotes Methylation of Akt1 in Cells

S. Frye, C. Arrowsmith, K. Pearce, 2023, bioRxiv.

An autoinhibited state of 53BP1 revealed by small molecule antagonists and protein engineering

S. Frye, M. Botuyan, G. Mer, 2023, bioRxiv.

Synthesis of 2-aminobenzophenones via rapid halogen-lithium exchange in the presence of a 2-amino-N-methoxy-N-methylbenzamide

S. Frye, M. Johnson, N. L. Valvano, 1991 .

Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer’s disease

A. Levey, S. Frye, K. Pearce, 2023, bioRxiv.

Small-molecule ligands of methyl-lysine binding proteins.

Jian Jin, Cen Gao, Robert Lam, 2011, Journal of medicinal chemistry.

Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds.

Dmitri Kireev, Stephen V Frye, S. Frye, 2010, Journal of medicinal chemistry.

Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.

Mindy I. Davis, D. Urban, Adam Yasgar, 2021, Journal of medicinal chemistry.

Inhibitors paradoxically prime kinases.

S. Frye, G. Johnson, 2009, Nature chemical biology.

PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components.

Laura E. Herring, S. Frye, K. Pearce, 2023, ACS chemical biology.

Structure–activity relationships of methyl-lysine reader antagonists

S. Frye, W. Janzen, O. Gozani, 2012 .

Chemical probes for methyl lysine reader domains.

S. Frye, L. James, 2016, Current opinion in chemical biology.

Unlocking the potential of chemical probes for methyl-lysine reader proteins.

S. Frye, 2015, Future medicinal chemistry.

An autoinhibited state of 53BP1 revealed by small molecule antagonists and protein engineering

S. Frye, M. Botuyan, G. Mer, 2023, bioRxiv.

Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.

S. Frye, M. Machius, M. Miley, 2016, ACS medicinal chemistry letters.

Discovery of Mer kinase inhibitors by virtual screening using Structural Protein-Ligand Interaction Fingerprints.

S. Frye, W. Janzen, D. Kireev, 2015, Bioorganic & medicinal chemistry.

Abstract 947: A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma

David B. Darr, N. Sharpless, S. Frye, 2014 .

Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia

S. Frye, W. Janzen, H. Earp, 2014 .

Bringing together the academic drug discovery community

P. Jeffrey Conn, Michelle Arkin, Stephen Frye, 2013, Nature Reviews Drug Discovery.

Prevention of chelation by an oxygen function through protection with a triisopropyl silyl group

S. Frye, E. Eliel, 1986 .

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, J. M. Shields, 2013, The Journal of clinical investigation.

UNC 569 , a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo

S. Frye, W. Janzen, H. Earp, 2013 .

Use of Protein Kinase–Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors

S. Frye, K. Pearce, Huanchen Wang, 2018, SLAS discovery : advancing life sciences R & D.

SETDB1 Triple Tudor Domain Ligand, (R,R)-59, Promotes Methylation of Akt1 in Cells.

S. Frye, C. Arrowsmith, K. Pearce, 2023, ACS chemical biology.

The Lipid Kinase PIP5K1C Regulates Pain Signaling and Sensitization

S. Frye, W. Janzen, M. Zylka, 2014, Neuron.

Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.

S. Frye, P. Maloney, S V Frye, 1995, Journal of medicinal chemistry.

Writing and Rewriting the Epigenetic Code of Cancer Cells: From Engineered Proteins to Small Molecules

S. Frye, P. Blancafort, Jian Jin, 2013, Molecular Pharmacology.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

S. Frye, M. Machius, M. Miley, 2013, Journal of medicinal chemistry.

Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors

S. Frye, M. Machius, M. Miley, 2017, ChemMedChem.

Discovery of Mer kinase inhibitors by virtual screening using Structural Protein-Ligand Interaction Fingerprints.

S. Frye, D. Kireev, M. Stashko, 2015, Bioorganic & medicinal chemistry.

TITLE: Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma

S. Frye, Xiaodong Wang, S. Eckhardt, 2018 .

The promise and peril of chemical probes (vol 11, pg 536, 2015)

John P. Overington, Jayme L. Dahlin, Christopher M. Austin, 2015 .